Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection.

High levels of antibodies to multiple antigens may be more strongly associated with protection from infection than antibodies to a single antigen. Antibody-associated protection against Plasmodium falciparum infection was assessed in a cohort of 68 adults living in an area of holoendemic malaria in Kenya. Antibodies to the pre-erythrocytic antigens circumsporozoite protein (CSP), liver-stage antigen-1 (LSA-1), thrombospondin-related adhesive protein (TRAP), and blood-stage antigens apical membrane antigen-1 (AMA-1), erythrocyte binding antigen-175 (EBA-175), and merozoite surface protein 1 (MSP-1) were tested. Peptides were used for CSP (NANP repeat) and LSA-1 (central repeat), and recombinant antigens were used for TRAP (aa D(48)-K(394)), AMA-1 (ectodomain, non-glycosylated), EBA-175 (non-glycosylated), and MSP-1 (MSP-1(19)). Weekly microscopy testing for P. falciparum infection was performed over a 12-week period after drug-mediated clearance of P. falciparum parasitemia. Individuals with high levels of IgG antibodies (> 2 arbitrary units) to CSP, LSA-1, and TRAP had a 57% decrease in the risk of infection (95% confidence interval = 20-77%, P = 0.016). This decreased risk remained significant after adjustment for age, prior parasitemia, bed net use, sickle cell trait, and village of residence. In contrast, protection against infection did not correlate with high levels of IgG antibodies to blood-stage antigens or IgM antibodies to pre-erythrocytic or blood-stage antigens. High levels of IgG antibodies to CSP, LSA-1, and TRAP may be useful immune correlates of protection against P. falciparum infection in malaria-endemic populations.

[1]  L. Marrama,et al.  Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. , 2005, Journal of Infectious Diseases.

[2]  D. Conway,et al.  Antibodies to the N-Terminal Block 2 of Plasmodium falciparum Merozoite Surface Protein 1 Are Associated with Protection against Clinical Malaria , 2004, Infection and Immunity.

[3]  C. John,et al.  Gamma Interferon Responses to Plasmodium falciparum Liver-Stage Antigen 1 and Thrombospondin-Related Adhesive Protein and Their Relationship to Age, Transmission Intensity, and Protection against Malaria , 2004, Infection and Immunity.

[4]  C. John,et al.  Evidence That Invasion-Inhibitory Antibodies Specific for the 19-kDa Fragment of Merozoite Surface Protein-1 (MSP-119) Can Play a Protective Role against Blood-Stage Plasmodium falciparum Infection in Individuals in a Malaria Endemic Area of Africa1 , 2004, The Journal of Immunology.

[5]  A. Hill,et al.  A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease , 2004, Nature Medicine.

[6]  Markus S. Mueller,et al.  A Role for Apical Membrane Antigen 1 during Invasion of Hepatocytes by Plasmodium falciparum Sporozoites* , 2004, Journal of Biological Chemistry.

[7]  C. John,et al.  Antibodies to the Plasmodium falciparum Antigens Circumsporozoite Protein, Thrombospondin-Related Adhesive Protein, and Liver-Stage Antigen 1 Vary by Ages of Subjects and by Season in a Highland Area of Kenya , 2003, Infection and Immunity.

[8]  David L. Tabb,et al.  A proteomic view of the Plasmodium falciparum life cycle , 2002, Nature.

[9]  C. John,et al.  Lymphocyte proliferation and antibody responses to Plasmodium falciparum liver-stage antigen-1 in a highland area of Kenya with seasonal variation in malaria transmission. , 2002, The American journal of tropical medicine and hygiene.

[10]  D. Conway,et al.  Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial , 2001, The Lancet.

[11]  L. Rénia,et al.  Expression of the erythrocyte-binding antigen 175 in sporozoites and in liver stages of Plasmodium falciparum. , 2001, The Journal of infectious diseases.

[12]  J. Kurtis,et al.  Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. , 2001, Trends in parasitology.

[13]  B. Nahlen,et al.  Cytokine Responses to Plasmodium falciparumLiver-Stage Antigen 1 Vary in Rainy and Dry Seasons in Highland Kenya , 2000, Infection and Immunity.

[14]  P. Ringwald,et al.  Immune response to Plasmodium falciparum liver stage antigen-1: geographical variations within Central Africa and their relationship with protection from clinical malaria. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[15]  S. Hoffman,et al.  The Complexity of Protective Immunity Against Liver-Stage Malaria1 2 , 2000, The Journal of Immunology.

[16]  S. Hoffman,et al.  CD4+ T-Cell- and Gamma Interferon-Dependent Protection against Murine Malaria by Immunization with Linear Synthetic Peptides from a Plasmodium yoelii17-Kilodalton Hepatocyte Erythrocyte Protein , 1999, Infection and Immunity.

[17]  A. Sultan.  Molecular mechanisms of malaria sporozoite motility and invasion of host cells. , 1999, International microbiology : the official journal of the Spanish Society for Microbiology.

[18]  J. Kurtis,et al.  Interleukin-10 Responses to Liver-Stage Antigen 1 Predict Human Resistance to Plasmodium falciparum , 1999, Infection and Immunity.

[19]  B. Lell,et al.  Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. , 1999, The Journal of infectious diseases.

[20]  B. Lell,et al.  Parasite antigen-specific interleukin-10 and antibody reponses predict accelerated parasite clearance in Plasmodium falciparum malaria. , 1999, European cytokine network.

[21]  G. Wortmann,et al.  Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. , 1998, The Journal of infectious diseases.

[22]  O. Branch,et al.  A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. , 1998, The American journal of tropical medicine and hygiene.

[23]  S Walters,et al.  T-cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic , 1997, Infection and immunity.

[24]  Patricia De la Vega,et al.  Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes , 1997, Infection and immunity.

[25]  Joe D. Cohen,et al.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.

[26]  S. Hoffman,et al.  Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity , 1996, The Journal of experimental medicine.

[27]  A. Holder,et al.  Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. , 1996, The Journal of infectious diseases.

[28]  Virander S. Chauhan,et al.  A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge , 1995, Infection and immunity.

[29]  P. Kalavathi,et al.  Analysis of sickle cell gene using polymerase chain reaction & restriction enzyme Bsu 361. , 1995, The Indian journal of medical research.

[30]  S. Hoffman,et al.  Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  L. BenMohamed,et al.  Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. , 1994, Journal of immunology.

[32]  D. Kaslow,et al.  Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae. , 1994, Molecular and biochemical parasitology.

[33]  O. Doumbo,et al.  Analysis of the human antibody response to thrombospondin-related anonymous protein of Plasmodium falciparum , 1993, Infection and immunity.

[34]  S. Hoffman,et al.  Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. , 1993, The American journal of tropical medicine and hygiene.

[35]  H. Bujard,et al.  Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells suggesting a role for this molecule in sporozoite invasion of hepatocytes. , 1993, The EMBO journal.

[36]  A. Crisanti,et al.  Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum in parasite-host cell interactions. , 1993, Parassitologia.

[37]  V. Nussenzweig,et al.  Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes , 1993, The Journal of experimental medicine.

[38]  W. Jarra,et al.  Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. , 1993, Molecular and biochemical parasitology.

[39]  V. Nussenzweig,et al.  Binding of malarial circumsporozoite protein to sulfatides [Gal(3-SO4)beta 1-Cer] and cholesterol-3-sulfate and its dependence on disulfide bond formation between cysteines in region II. , 1992, Molecular and biochemical parasitology.

[40]  C. Chougnet,et al.  Lymphoproliferative responses to synthetic peptides from merozoite ring-infected erythrocyte surface antigen and circumsporozoite protein: a longitudinal study during a falciparum malaria episode. , 1991, The American journal of tropical medicine and hygiene.

[41]  V. Nussenzweig,et al.  Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection , 1980, The Journal of experimental medicine.